- Previous Close
1.2000 - Open
1.1700 - Bid 1.0700 x 200
- Ask 1.1400 x 100
- Day's Range
1.0800 - 1.1800 - 52 Week Range
0.2560 - 4.7800 - Volume
456,864 - Avg. Volume
2,107,528 - Market Cap (intraday)
210.061M - Beta (5Y Monthly) -1.05
- PE Ratio (TTM)
3.48 - EPS (TTM)
0.3100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.00
Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.
tevogen.comRecent News: TVGN
View MorePerformance Overview: TVGN
Trailing total returns as of 3/31/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TVGN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TVGN
View MoreValuation Measures
Market Cap
210.06M
Enterprise Value
217.50M
Trailing P/E
3.44
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
4.18
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-542.18%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-4.5M
Diluted EPS (ttm)
0.3100
Balance Sheet and Cash Flow
Total Cash (mrq)
2.33M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
8.62M